Corvus Pharmaceuticals Appoints David Moore to Board of Directors
Corvus Pharmaceuticals (NASDAQ: CRVS) announced on October 2, 2025 the appointment of David Moore to its Board of Directors. Mr. Moore is Executive Vice President, US Operations and President at Novo Nordisk Inc., with 27 years of industry experience across strategy, commercial, market access, business development and private equity. Management expects his commercial and corporate development experience to support advancement of Corvus’ ITK inhibitor pipeline.
Corvus Pharmaceuticals (NASDAQ: CRVS) ha annunciato il 2 ottobre 2025 la nomina di David Moore nel suo Consiglio di amministrazione. Il signor Moore è Vicepresidente Esecutivo, Operations US e Presidente presso Novo Nordisk Inc., con 27 anni di esperienza nel settore in ambiti quali strategia, commerciale, accesso al mercato, sviluppo commerciale e private equity. La direzione si aspetta che la sua esperienza commerciale e nello sviluppo corporativo supporti l'avanzamento della pipeline di ITK inhibitor di Corvus.
Corvus Pharmaceuticals (NASDAQ: CRVS) anunció el 2 de octubre de 2025 el nombramiento de David Moore en su Junta Directiva. El Sr. Moore es Vicepresidente Ejecutivo, Operaciones en EE. UU. y Presidente de Novo Nordisk Inc., con 27 años de experiencia en la industria abarcando estrategia, comercial, acceso al mercado, desarrollo comercial y private equity. Se espera que su experiencia en ventas y desarrollo corporativo apoye el avance de la cartera de inhibidores ITK.
Corvus Pharmaceuticals (NASDAQ: CRVS)는 2025년 10월 2일에 이사회에 David Moore를 임명했다고 발표했다. Moore 씨는 Novo Nordisk Inc.의 미국 운영 담당 부사장 겸 사장이며, 전략, 상업, 시장 접근, 비즈니스 개발 및 사모펀드에 걸친 27년의 업계 경험을 보유하고 있다. 경영진은 그의 상업 및 기업 개발 경험이 Corvus의 ITK inhibitor 파이프라인의 발전을 지원할 것이라고 기대한다.
Corvus Pharmaceuticals (NASDAQ: CRVS) a annoncé le 2 octobre 2025 la nomination de David Moore au conseil d'administration. M. Moore est vice-président exécutif, Opérations américaines et président chez Novo Nordisk Inc., avec 27 ans d'expérience dans l'industrie couvrant la stratégie, le commercial, l'accès au marché, le développement commercial et le capital-investissement. La direction s'attend à ce que son expérience commerciale et en développement d'entreprise soutienne l'avancement du portefeuille ITK inhibitor de Corvus.
Corvus Pharmaceuticals (NASDAQ: CRVS) gab am 2. Oktober 2025 die Ernennung von David Moore in den Vorstand bekannt. Herr Moore ist Executive Vice President, US Operations und Präsident bei Novo Nordisk Inc., mit 27 Jahren Branchenerfahrung in den Bereichen Strategie, Commercial, Marktzugang, Geschäftsentwicklung und Private Equity. Das Management erwartet, dass seine kommerzielle und unternehmerische Entwicklungserfahrung die Weiterentwicklung der ITK inhibitor-Pipeline von Corvus unterstützt.
أعلنت كورفوس للأدوية (ناسداك: CRVS) في 2 أكتوبر 2025 تعيين ديفيد مور في مجلس إدارتها. السيد مور هو نائب الرئيس التنفيذي للعمليات الأمريكية والرئيس في Novo Nordisk Inc.، مع 27 عامًا من الخبرة في الصناعة عبر الاستراتيجية والتجاري والوصول إلى السوق وتطوير الأعمال والاستثمار الخاص. تتوقع الإدارة أن خبرته التجارية وخبرة تطوير الأعمال ستدعم تقدم خط أنابيب ITK inhibitor الخاص بكورفوس.
Corvus Pharmaceuticals (NASDAQ: CRVS) 于 2025 年 10 月 2 日 宣布任命 David Moore 为董事会成员。莫尔先生现任 Novo Nordisk Inc. 的美国运营执行副总裁兼总裁，拥有在战略、商业、市场准入、业务拓展和私募股权等领域的 27 年行业经验。管理层预计他的商业及企业发展经验将有助于推动 Corvus 的 ITK inhibitor 管线的推进。
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that David Moore, Executive Vice President, US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., has been appointed to the company’s Board of Directors. Mr. Moore brings a wealth of experience from his 27-year career in the industry, including broad expertise across strategy, commercial, market access, business development and investing from working in both large cap pharmaceutical and biotech companies and within private equity.
“We are excited to welcome David to the Board,” said Richard A. Miller, M.D., chairman, president, and chief executive officer of Corvus. “His experience leading Novo’s U.S. business, including one of the most successful GLP-1 franchises that includes Ozempic, Wegovy and Rybelsus, along with his work in corporate strategy and business development, is anticipated to be an important strategic resource as we work to maximize the potential of our ITK inhibitor platform.”
“Corvus has a compelling opportunity to develop ITK inhibition across cancer and immune diseases, leveraging a novel mechanism of action based on strong science with demonstrated potential in areas of significant patient need,” said Mr. Moore. “I am honored to join the Corvus Board of Directors and look forward to working with the team as the Company continues to advance its pipeline and growth opportunities.”
Mr. Moore currently serves as Executive Vice President, US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., the US operating subsidiary of Novo Nordisk A/S. He has held positions of increasing responsibility at Novo Nordisk, including Executive Vice President, Corporate Development and Senior Vice President, Commercial at Novo Nordisk, Inc. Mr. Moore’s other experience also includes serving as an investment partner at Gurnet Point Capital, a life science focused private equity firm; chief executive officer of Lysovant Sciences, a Roivant company; and president and chief commercial officer of Cempra Pharmaceuticals. Mr. Moore began his career at Johnson & Johnson, where he spent 14 years in roles of increasing responsibility across sales, marketing and business development. Mr. Moore holds an MBA in Marketing from Lehigh University and a Bachelor of Science in Biology from Towson University.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the company on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements related to the potential of the Company’s product candidates including soquelitinib, the advancement of ITK inhibition and the opportunities it provides, continued advancement of the Company’s clinical pipeline, and Mr. Moore’s expected contributions to the Company’s board of directors. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-Q for the second quarter ended June 30, 2025, filed with the Securities and Exchange Commission on August 7, 2025, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company’s ability to enroll sufficient number of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and foreign countries; the costs of clinical trials may exceed expectations; and the Company’s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
Who did Corvus (CRVS) appoint to its board on October 2, 2025?
What experience does David Moore bring to Corvus' board (CRVS)?
How might David Moore impact Corvus' ITK inhibitor pipeline (CRVS)?
When was the Corvus (CRVS) board appointment announced?
Does the press release for Corvus (CRVS) include financial guidance or clinical readouts?
What roles has David Moore held before joining Corvus' board (CRVS)?
